| 1 |
Liu X, Cui H, Li M, Chai Z, Wang H, Jin X, Dai F, Liu Y, Zhou B. Tumor killing by a dietary curcumin mono-carbonyl analog that works as a selective ROS generator via TrxR inhibition. Eur J Med Chem 2023;250:115191. [PMID: 36758308 DOI: 10.1016/j.ejmech.2023.115191] [Reference Citation Analysis]
|
| 2 |
Chang B, Xu Q, Guo H, Zhong M, Shen R, Zhao L, Zhao J, Ma T, Chu Y, Zhang J, Fang J. Puromycin Prodrug Activation by Thioredoxin Reductase Overcomes Its Promiscuous Cytotoxicity. J Med Chem 2023;66:3250-61. [PMID: 36855911 DOI: 10.1021/acs.jmedchem.2c01509] [Reference Citation Analysis]
|
| 3 |
He YL, Zhong M, Song ZL, Shen YK, Zhao L, Fang J. Synthesis and discovery of Baylis-Hillman adducts as potent and selective thioredoxin reductase inhibitors for cancer treatment. Bioorg Med Chem 2023;79:117169. [PMID: 36657375 DOI: 10.1016/j.bmc.2023.117169] [Reference Citation Analysis]
|
| 4 |
Zhang J, Li X, Zhao Z, Cai W, Fang J. Thioredoxin Signaling Pathways in Cancer. Antioxid Redox Signal 2023;38:403-24. [PMID: 35686449 DOI: 10.1089/ars.2022.0074] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 5 |
Zhang J, Liu P, Chen J, Yao D, Liu Q, Zhang J, Zhang HW, Leung EL, Yao XJ, Liu L. Upgrade of chrysomycin A as a novel topoisomerase II inhibitor to curb KRAS-mutant lung adenocarcinoma progression. Pharmacol Res 2023;187:106565. [PMID: 36414124 DOI: 10.1016/j.phrs.2022.106565] [Reference Citation Analysis]
|
| 6 |
Liu X, Wang X. Recent advances on the structural modification of parthenolide and its derivatives as anticancer agents. Chinese Journal of Natural Medicines 2022;20:814-829. [DOI: 10.1016/s1875-5364(22)60238-3] [Reference Citation Analysis]
|
| 7 |
Xu Q, Zhang J, Zhao Z, Chu Y, Fang J. Revealing PACMA 31 as a new chemical type TrxR inhibitor to promote cancer cell apoptosis. Biochim Biophys Acta Mol Cell Res 2022;1869:119323. [PMID: 35793738 DOI: 10.1016/j.bbamcr.2022.119323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 8 |
Zhao J, Ma T, Chang B, Fang J. Recent Progress on NIR Fluorescent Probes for Enzymes. Molecules 2022;27:5922. [DOI: 10.3390/molecules27185922] [Reference Citation Analysis]
|
| 9 |
Wang X, Sun B, Ye Z, Zhang W, Xu W, Gao S, Zhou N, Wu F, Shen J. Enzyme-Responsive COF-Based Thiol-Targeting Nanoinhibitor for Curing Bacterial Infections. ACS Appl Mater Interfaces 2022. [PMID: 35989491 DOI: 10.1021/acsami.2c08845] [Reference Citation Analysis]
|
| 10 |
Song ZL, Zhao L, Ma T, Osama A, Shen T, He Y, Fang J. Progress and perspective on hydrogen sulfide donors and their biomedical applications. Med Res Rev 2022. [PMID: 35657029 DOI: 10.1002/med.21913] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 11 |
Zhang J, Chen Y, Fang J. Targeting thioredoxin reductase by micheliolide contributes to radiosensitizing and inducing apoptosis of HeLa cells. Free Radic Biol Med 2022:S0891-5849(22)00183-6. [PMID: 35561844 DOI: 10.1016/j.freeradbiomed.2022.05.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 12 |
Xu Q, Zhang J. Novel strategies for targeting the thioredoxin system for cancer therapy. Expert Opin Drug Discov 2022. [PMID: 35193453 DOI: 10.1080/17460441.2022.2045270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
